http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 06:32:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Medtronic%2C+Inc.+%28MDT%29/26156166.html <p>Needham analyst Michael Matson reiterated a Buy rating and $120.00 price target on Medtronic, Inc. (NYSE: MDT).</p><p>The analyst commented: "We have updated our F4Q26 EPS estimate to reflect dilution from the MiniMed IPO (MMED - Not Rated). MDT had previously indicated that the MMED IPO would result in $0.01-0.02 of EPS dilution per month. However, management's implied F4Q26 EPS guidance of $1.64-1.68 did not reflect the MMED dilution due to uncertainty around the timing of the IPO. With the IPO now completed, we lower our F4Q26E EPS estimate by $0.04 to $1.64 from $1.68 and our FY26E EPS to $5.59 http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Medtronic%2C+Inc.+%28MDT%29/26156166.html Fri, 13 Mar 2026 06:32:58 -0400 MDT http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Press+Releases/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html <ul><li><em>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs</em><br/></li></ul> <p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the http://www.streetinsider.com/Globe+Newswire/Orchestra+BioMed+Reports+Full+Year+2025+Financial+Results+and+Provides+Fourth+Quarter+Business+Update/26149755.html Thu, 12 Mar 2026 08:17:00 -0400 A.60005114 MDT O.06028868 O.23130379 O.49531689 OBIO http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Reiterates+Outperform+Rating+on+Medtronic%2C+Inc.+%28MDT%29%3A+acquisition+an+%22incremental+positive%22/26137372.html <p>Leerink Partners analyst Mike Kratky reiterated an Outperform rating and $119.00 price target on Medtronic, Inc. (NYSE: MDT)</p><p>The analyst commented, "Bottom Line: We see MDT's acquisition of Scientia Vascular as an incremental positive, supporting an accelerating growth algorithm via M&A. Having visited Scientia's Utah facility last year, we are big fans of the company's underlying innovative technology and this deal in general. Overall, we believe this deal underscores management's stated goals of improving both the growth and margin profile of the business in high growth verticals. We look forward to delving more into management's outlook, overall strategy, and details around http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Reiterates+Outperform+Rating+on+Medtronic%2C+Inc.+%28MDT%29%3A+acquisition+an+%22incremental+positive%22/26137372.html Tue, 10 Mar 2026 10:30:09 -0400 MDT http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Medtronic%2C+Inc.+%28MDT%29%3A+%22glad+to+see+MDT+increasingly+pursue+tuck-in+acquisitions%22/26137010.html <p>Needham analyst Michael Matson reiterated a Buy rating and $120.00 price target on Medtronic, Inc. (NYSE: MDT)</p><p>The analyst commented, "This morning, MDT announced an agreement to acquire Scientia Vascular (private) for ~$550M of cash. The deal is expected to close in F1H27 and MDT expects the deal to be minimally dilutive to its adjusted EPS in the FY27 and accretive thereafter. Scientia Vascular has a small portfolio of neurovascular access products, including guidewires and catheters and MDT noted that the acquisition positions it with a full suite of products across both hemorrhagic and acute ischemic stroke. We believe that the http://www.streetinsider.com/Analyst+Comments/Needham+Reiterates+Buy+Rating+on+Medtronic%2C+Inc.+%28MDT%29%3A+%22glad+to+see+MDT+increasingly+pursue+tuck-in+acquisitions%22/26137010.html Tue, 10 Mar 2026 09:43:04 -0400 MDT http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Hold+Rating+on+Medtronic%2C+Inc.+%28MDT%29+amid+acquisition+announcement/26136958.html <p>Truist Securities analyst Richard Newitter reiterated a Hold rating and $103.00 price target on Medtronic, Inc. (NYSE: MDT)</p><p>The analyst commented, "This AM Medtronic (MDT, Hold) announced an agreement to acquire Scientia Vascular [Private], a neurovascular access company for $550M upfront plus potential undisclosed earn-out and milestone payments. Historical revenue terms or growth for Scientia were undisclosed, so it's difficult to say what the valuation was, but at least from a strategic perspective the deal provides an additional product set that could help drive growth acceleration in MDT's neuro franchise. Neurovascular has been an area that has been underperforming (declining y/y http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Hold+Rating+on+Medtronic%2C+Inc.+%28MDT%29+amid+acquisition+announcement/26136958.html Tue, 10 Mar 2026 09:31:55 -0400 MDT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html <p>Piper Sandler analyst Adam C. Maeder shares Key Takeaways From the Cardiovascular Research Technologies meeting.</p><p>The analyst commented: "We attended the CRT (Cardiovascular Research Technologies) Meeting. Our takeaways include: (1) There was lots of discussion around the MDT low-risk TAVR data and the reintervention signal seen at 6 and 7-years. We think MDT has some plausible explanations/rebuttals, however, we think the headlines will carry-the-day and we expect some share to change hands (we see EW as the primary beneficiary). (2) Roughly 3/4 of the physicians that voted during the “CRT Predicts” session that CHAMPION-AF will meet its primary endpoints later this http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html Tue, 10 Mar 2026 08:35:59 -0400 ABT BSX EW MDT NSPR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html <p>Piper Sandler analyst Adam C. Maeder shares Key Takeaways From the Cardiovascular Research Technologies meeting.</p><p>The analyst commented: "We attended the CRT (Cardiovascular Research Technologies) Meeting. Our takeaways include: (1) There was lots of discussion around the MDT low-risk TAVR data and the reintervention signal seen at 6 and 7-years. We think MDT has some plausible explanations/rebuttals, however, we think the headlines will carry-the-day and we expect some share to change hands (we see EW as the primary beneficiary). (2) Roughly 3/4 of the physicians that voted during the “CRT Predicts” session that CHAMPION-AF will meet its primary endpoints later this http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html Tue, 10 Mar 2026 08:35:59 -0400 ABT BSX EW MDT NSPR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html <p>Piper Sandler analyst Adam C. Maeder shares Key Takeaways From the Cardiovascular Research Technologies meeting.</p><p>The analyst commented: "We attended the CRT (Cardiovascular Research Technologies) Meeting. Our takeaways include: (1) There was lots of discussion around the MDT low-risk TAVR data and the reintervention signal seen at 6 and 7-years. We think MDT has some plausible explanations/rebuttals, however, we think the headlines will carry-the-day and we expect some share to change hands (we see EW as the primary beneficiary). (2) Roughly 3/4 of the physicians that voted during the “CRT Predicts” session that CHAMPION-AF will meet its primary endpoints later this http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html Tue, 10 Mar 2026 08:35:59 -0400 ABT BSX EW MDT NSPR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html <p>Piper Sandler analyst Adam C. Maeder shares Key Takeaways From the Cardiovascular Research Technologies meeting.</p><p>The analyst commented: "We attended the CRT (Cardiovascular Research Technologies) Meeting. Our takeaways include: (1) There was lots of discussion around the MDT low-risk TAVR data and the reintervention signal seen at 6 and 7-years. We think MDT has some plausible explanations/rebuttals, however, we think the headlines will carry-the-day and we expect some share to change hands (we see EW as the primary beneficiary). (2) Roughly 3/4 of the physicians that voted during the “CRT Predicts” session that CHAMPION-AF will meet its primary endpoints later this http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html Tue, 10 Mar 2026 08:35:59 -0400 ABT BSX EW MDT NSPR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html <p>Piper Sandler analyst Adam C. Maeder shares Key Takeaways From the Cardiovascular Research Technologies meeting.</p><p>The analyst commented: "We attended the CRT (Cardiovascular Research Technologies) Meeting. Our takeaways include: (1) There was lots of discussion around the MDT low-risk TAVR data and the reintervention signal seen at 6 and 7-years. We think MDT has some plausible explanations/rebuttals, however, we think the headlines will carry-the-day and we expect some share to change hands (we see EW as the primary beneficiary). (2) Roughly 3/4 of the physicians that voted during the “CRT Predicts” session that CHAMPION-AF will meet its primary endpoints later this http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%27s+Key+Takeaways+From+CRT+2026/26136096.html Tue, 10 Mar 2026 08:35:59 -0400 ABT BSX EW MDT NSPR http://www.streetinsider.com/Mergers+and+Acquisitions/Medtronic+to+acquire+Scientia+Vascular+for+%24550+million/26134996.html <p>Medtronic plc (NYSE: MDT) announced it entered into a definitive agreement to acquire Scientia Vascular for $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments.</p> <p>Scientia Vascular is a private company based in Salt Lake City, Utah, with approximately 310 employees. The company develops guidewires and catheters designed to improve access through complex cerebral vasculature during neurovascular procedures.</p> <p>The acquisition aims to complement Medtronic's existing neurovascular portfolio by adding access products that work with the company's therapeutic devices. Scientia's technology focuses on improving navigability through the brain's complex blood vessel network, which can present challenges for physicians treating http://www.streetinsider.com/Mergers+and+Acquisitions/Medtronic+to+acquire+Scientia+Vascular+for+%24550+million/26134996.html Tue, 10 Mar 2026 06:45:18 -0400 MDT O.23130379 http://www.streetinsider.com/Mergers+and+Acquisitions/Medtronic+to+acquire+Scientia+Vascular+for+%24550+million/26134996.html <p>Medtronic plc (NYSE: MDT) announced it entered into a definitive agreement to acquire Scientia Vascular for $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments.</p> <p>Scientia Vascular is a private company based in Salt Lake City, Utah, with approximately 310 employees. The company develops guidewires and catheters designed to improve access through complex cerebral vasculature during neurovascular procedures.</p> <p>The acquisition aims to complement Medtronic's existing neurovascular portfolio by adding access products that work with the company's therapeutic devices. Scientia's technology focuses on improving navigability through the brain's complex blood vessel network, which can present challenges for physicians treating http://www.streetinsider.com/Mergers+and+Acquisitions/Medtronic+to+acquire+Scientia+Vascular+for+%24550+million/26134996.html Tue, 10 Mar 2026 06:45:18 -0400 MDT O.23130379 http://www.streetinsider.com/Press+Releases/Medtronic+to+acquire+Scientia+Vascular%2C+marrying+access+and+therapeutic+portfolios+for+neurovascular+care/26134992.html <div class="xn-content"> <p class="prntac">Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'</p><p><span class="legendSpanClass">GALWAY, <location value="LC/ie" idsrc="xmltag.org" >Ireland</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at <money>$550 million</money>, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.</p><p>Scientia is a private company operating in <location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >Salt Lake City, Utah</location>, with approximately 310 employees. Under founder and current chief technology officer <person>John Lippert</person>, the company has developed best-in-class access http://www.streetinsider.com/Press+Releases/Medtronic+to+acquire+Scientia+Vascular%2C+marrying+access+and+therapeutic+portfolios+for+neurovascular+care/26134992.html Tue, 10 Mar 2026 06:45:00 -0400 MDT O.23130379 http://www.streetinsider.com/Press+Releases/Medtronic+to+acquire+Scientia+Vascular%2C+marrying+access+and+therapeutic+portfolios+for+neurovascular+care/26134992.html <div class="xn-content"> <p class="prntac">Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'</p><p><span class="legendSpanClass">GALWAY, <location value="LC/ie" idsrc="xmltag.org" >Ireland</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at <money>$550 million</money>, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.</p><p>Scientia is a private company operating in <location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >Salt Lake City, Utah</location>, with approximately 310 employees. Under founder and current chief technology officer <person>John Lippert</person>, the company has developed best-in-class access http://www.streetinsider.com/Press+Releases/Medtronic+to+acquire+Scientia+Vascular%2C+marrying+access+and+therapeutic+portfolios+for+neurovascular+care/26134992.html Tue, 10 Mar 2026 06:45:00 -0400 MDT O.23130379